Type	Entity	Source evidence	Confidence	Extractor
gene	MYC	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.”	0.98	phenotype_alias_lexicon_v2
gene	BCL2	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1
gene	BCL6	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1

PMID 36287175 | PMCID PMC9898117 | DOI 10.1158/1541-7786.MCR-19-1209 · Molecular cancer research : MCR · 2023 · 6 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	MYC	“TLR4 activation in turn caused c-JUN-dependent and STAT3-dependent translocations of MYC loci to suppress transactivation of CD95/FAS.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“UNLABELLED: Synergism between obesity and virus infection promotes the development of B-cell lymphoma.”	0.98	phenotype_alias_lexicon_v2
gene	STAT3	“Gut-derived Endotoxin-TLR4 Signaling Drives MYC-Ig Translocation to Promote Lymphoproliferation through c-JUN and STAT3 Activation.”	0.98	hgnc_dict_v1
gene	TLR4	“TLR4 activation in turn caused c-JUN-dependent and STAT3-dependent translocations of MYC loci to suppress transactivation of CD95/FAS.”	0.98	hgnc_dict_v1

PMID 34679437 | PMCID PMC8535125 | DOI 10.3390/diagnostics11101739 · Diagnostics (Basel, Switzerland) · 2021 · 7 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	MYC	“Recently miRNAs were also identified to act either as oncogenes or tumor suppressors in DLBCL pathology by altering the expression levels of some of the known DLBCL related oncogenes. i.e., miR-155, miR-17-92 and miR-21 act as oncogenes by altering the expression levels of MYC, SHIP and FOXO1, respectively, conversely; miR-34a, mir-144 and miR-181a act as tumor suppressors by altering the expression levels of SIRT1, BCL6 and CARD11, respectively.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma (NHL), arising from different stages of B-cell differentiation whose pathogenesis involves miRNAs.”	0.98	phenotype_alias_lexicon_v2
gene	BCL6	“These genetic mutations are involved in epigenetic modification, ability to escape immunosurveillance, impaired BCL6 and NF-κβ signaling pathways and blocking terminal differentiation.”	0.98	hgnc_dict_v1
gene	FOXO1	“Recently miRNAs were also identified to act either as oncogenes or tumor suppressors in DLBCL pathology by altering the expression levels of some of the known DLBCL related oncogenes. i.e., miR-155, miR-17-92 and miR-21 act as oncogenes by altering the expression levels of MYC, SHIP and FOXO1, respectively, conversely; miR-34a, mir-144 and miR-181a act as tumor suppressors by altering the expression levels of SIRT1, BCL6 and CARD11, respectively.”	0.98	hgnc_dict_v1